In children with idiopathic short stature (ISS), high-dose growth hormone (GH) therapy produces a significant increase in height, but its therapeutic benefit may be limited because it accelerates bone maturation and induces an earlier onset of puberty, according to a recent report.
Dr. J. M. Wit, from Leiden University Medical Center in the Netherlands, and colleagues assessed the 5-year outcomes of 35 children with ISS who were randomized to receive GH therapy or no treatment.
The subjects included 9 girls, 4 to 8 years of age, and 26 boys, 4 to 10 years of age. At enrollment, none of the children had signs of puberty and all had normal body proportions. The researchers’ findings are published in the September issue of the Archives of Disease in Childhood.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!